ストックスクリーナーアプリを入手
3.42
1.44%
-0.06
前日終値:
$3.48
開ける：
$3.51
24時間の取引高:
164.97K
Relative Volume:
1.09
時価総額：
$1.22B
収益：
$842.96M
当期純損益:
$-185.63M
株価収益率:
-6.5031
EPS:
-0.5259
ネットキャッシュフロー:
$-228.52M
1週間 パフォーマンス:
-2.56%
1か月 パフォーマンス:
-8.78%
6か月 パフォーマンス:
-9.97%
1年 パフォーマンス:
-23.44%
1日の値動き範囲:
$3.43
$3.51
1週間の範囲:
$3.43
$3.69
52週間の値動き範囲:
$2.84
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.43 | 1.24B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.40 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
129.11 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.18 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.90 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
474.59 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-03 | 開始されました | Berenberg | Buy |
| 2025-04-24 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-10-07 | ダウングレード | Jefferies | Buy → Hold |
| 2024-08-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-07-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-04-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-08 | アップグレード | Citigroup | Neutral → Buy |
| 2023-04-04 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-16 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-08-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2022-01-07 | 再開されました | Citigroup | Neutral |
すべてを表示
Evotec Se Adr (EVO) 最新ニュース
Antibody Optimization Service (Affinity Maturation, Humanization, Phage Display, AI-based Computational Optimization) Market Trends Analysis and Growth Forecast Report 2025-2033 - GlobeNewswire Inc.
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? - Finviz
Financial Review: Evotec (NASDAQ:EVO) & Savara (NASDAQ:SVRA) - Defense World
JustEvotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Chartmill
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Chartmill
Taxes of Evotec SE Sponsored ADR – LSX:A0QZ3J - TradingView — Track All Markets
EvotecHow Low A Company May Go While Still Being Attractive (NASDAQ:EVO) - Seeking Alpha
Evotec Aktie | DE0005664809 | ETR:EVT | News & Aktienkurs | FRA:EVT - LYNX Online Broker
Evotec AG Earnings Call: Resilience Amidst Challenges - MSN
Evotec AG Reports Strategic Shift Amid Mixed Performance - MSN
Annual General Meeting - Evotec
Investor Relations - Evotec
Evotec shares tumble 9% as drug discovery segment weakens - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com UK
EVT Stock Price and Chart — XETR:EVT - TradingView
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com UK
Bayer, BioNxt Solutions, Evotec – falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? - kapitalerhoehungen.de
Evotec SE Sponsored ADR Trade Ideas — LSX:A0QZ3J - TradingView — Track All Markets
Evotec Stock: Some Recovery Has Come, Much More Is Expected (NASDAQ:EVO) - Seeking Alpha
Evotec SE (NASDAQ: EVO) Announces Departure of Chief Operating Officer Dr. Craig Johnstone - Kalkine Media
Markets Brief: Are Bank Stocks Expensive? - Morningstar
ProShares Nanotechnology ETF Holdings - Quiver Quantitative
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid By Investing.com - Investing.com South Africa
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar Canada
Earnings call: Evotec SE meets 2023 guidance, appoints new CEO - Investing.com
Evotec and Variant Bio partner to develop fibrosis treatments - Investing.com
Sandoz Group AG-ADR (SDZNY) Stock Price, News & Analyst Forecast - eToro
Evotec Se Adr (EVO) 財務データ
収益
当期純利益
現金流量
EPS
0.04%
9.18%
大文字化:
|
ボリューム (24 時間):